p53 as a predictor for chemotherapy response in CLL cells

References

• Rai K R, Sawitsky A, Cronkite E P, Chanana A D, Levy R N, Pasternack B S. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J L, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Witzig T E, Fink S R, Jenkins R B, Paternoster S F, Smoley S A, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Onc 2006; 28: 4634–4641
   Web of Science ®Google Scholar
• Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics 1997; 42: 367–377
   Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Chevalier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahe B, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 142–150
   PubMed Web of Science ®Google Scholar
• Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predicator of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar
• Lynch C J, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 2006; 25: 3463–3470
   PubMed Web of Science ®Google Scholar
• Pettitt A R, Sherrington P D, Stewart G, Cawley J C, Taylor A M, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001; 98: 814–822
   PubMed Web of Science ®Google Scholar
• Oscier D G, Gardiner A C, Mould S J, Glide S, Davis Z A, Ibbotson R E, et al. Multivariate analysis if prognostic factors in CLL Clinical stage, IGVH gene mutational status, and loss or mutationof the p53 gene are independent prognostic factors. Blood 2002; 100: 1177–1184
   PubMed Web of Science ®Google Scholar
• el Rouby S, Thomas A, Costin D, Rosenberg C R, Potmesil M, Silber R, Newcomb E W, et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452–3459
   PubMed Web of Science ®Google Scholar
• Byrd J C, Gribben J G, Peterson B L, Grever M R, Lozanski G, Lucas D M, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437–443
   PubMed Web of Science ®Google Scholar
• Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd P J, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet 1999; 353: 26–29
   PubMed Web of Science ®Google Scholar
• Schaffiner C, Stilgenbauer S, Rappold G, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 748–753
   PubMed Web of Science ®Google Scholar
• Turgut B, Vural O, Pala F S, Pamuk G E, Tabakcioğlu K, Demir M, et al. 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. Leuk Lymphoma 2007; 48: 311–320
   PubMed Web of Science ®Google Scholar
• Chipuk J E, Green D R. Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13: 994–1002
   PubMed Web of Science ®Google Scholar
• Carter A, Lin K, Sherrington P D, Pettitt A R. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425–428
   PubMed Web of Science ®Google Scholar